Cwm LLC Acquires 6,855 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Cwm LLC boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 58.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,653 shares of the biotechnology company’s stock after purchasing an additional 6,855 shares during the quarter. Cwm LLC’s holdings in ADMA Biologics were worth $370,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. boosted its stake in ADMA Biologics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 746 shares during the period. GF Fund Management CO. LTD. boosted its stake in ADMA Biologics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 1,089 shares during the period. KBC Group NV lifted its position in shares of ADMA Biologics by 11.5% in the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 1,154 shares during the period. PFG Investments LLC lifted its position in shares of ADMA Biologics by 0.6% in the 1st quarter. PFG Investments LLC now owns 222,809 shares of the biotechnology company’s stock worth $4,421,000 after acquiring an additional 1,301 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of ADMA Biologics by 0.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 511,526 shares of the biotechnology company’s stock worth $8,773,000 after acquiring an additional 1,559 shares during the period. Institutional investors own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares of the company’s stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares of the company’s stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 464,621 shares of company stock valued at $9,644,269. Corporate insiders own 3.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 8th.

ADMA Biologics Trading Up 4.0%

Shares of ADMA opened at $18.01 on Friday. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The stock has a 50 day simple moving average of $18.98 and a 200-day simple moving average of $18.72. The stock has a market cap of $4.30 billion, a PE ratio of 21.19 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period in the previous year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 40.2% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.